Cargando…

Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT)

ZD2767P, a nitrogen mustard glutamate prodrug, is currently being evaluated in Phase 1 clinical trials of antibody directed enzyme prodrug therapy (ADEPT). There was no significant relationship between basal glutathione (GSH) concentration and sensitivity to ZD2767P + carboxpeptidase G2 (CPG2) in co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Monks, N R, Calvete, J A, Curtin, N J, Blakey, D C, East, S J, Newell, D R
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2000
Materias:	Regular Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363482/ https://www.ncbi.nlm.nih.gov/pubmed/10901381 http://dx.doi.org/10.1054/bjoc.2000.1240

Ejemplares similares

Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue
por: Monks, N R, et al.
Publicado: (2001)

Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material
por: Webley, S D, et al.
Publicado: (2001)

A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours
por: Francis, R J, et al.
Publicado: (2002)

Development of ZD2767P–carboxypeptidase G2–ultrasound therapy against cisplatin-resistant cancer
por: Yu, Tinghe, et al.
Publicado: (2023)

Ultrasonically Enhanced ZD2767P–Carboxypeptidase G2 Deactivates Cisplatin-Resistant Human Lung Cancer Cells
por: Liu, Qianfen, et al.
Publicado: (2022)

Plasma clearance of an antibody--enzyme conjugate in ADEPT by monoclonal anti-enzyme: its effect on prodrug activation in vivo.
por: Rogers, G. T., et al.
Publicado: (1995)

Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT)
por: Mayer, A, et al.
Publicado: (2004)

Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging
por: Robinson, S P, et al.
Publicado: (2003)

Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs.
por: Blakey, D. C., et al.
Publicado: (1995)

PDEPT: polymer-directed enzyme prodrug therapy
por: Satchi, R, et al.
Publicado: (2001)

Glutathione-linked enzymes in benign and malignant oesophageal tissue
por: Levy, R D, et al.
Publicado: (1999)

Vérification de la conformité de colis de transport de radionucléides Type A modèles 2767R et 2767T
por: Greffion, Chloe
Publicado: (2016)

ADEPT IN THE SCIENCES
Publicado: (1963)

Additive interaction of gefitinib (‘Iressa’, ZD1839) and ionising radiation in human tumour cells in vitro
por: Giocanti, N, et al.
Publicado: (2004)

Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug
por: Cheng, T L, et al.
Publicado: (1999)

Genome Sequence of the Autotrophic Acetogen Clostridium magnum DSM 2767
por: Uhlig, Ronny, et al.
Publicado: (2016)

Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport
por: Smith, P G, et al.
Publicado: (2000)

Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro
por: Bowman, K J, et al.
Publicado: (2001)

Mathematical and experimental analysis of localization of anti-tumour antibody–enzyme conjugates
por: Jackson, T L, et al.
Publicado: (1999)

Tumour biomechanical response to the vascular disrupting agent ZD6126 in vivo assessed by magnetic resonance elastography
por: Li, J, et al.
Publicado: (2014)

Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126
por: Bozec, A, et al.
Publicado: (2006)

New guidelines for research in airway device evaluation: time for an updated approach (ADEPT-2) to the Difficult Airway Society’s ‘ADEPT’ strategy?
por: Athanassoglou, V., et al.
Publicado: (2022)

ZD6474 – clinical experience to date
por: Heymach, J V
Publicado: (2005)

A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer
por: Houba, P H J, et al.
Publicado: (2001)

Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma
por: Fens, M H A M, et al.
Publicado: (2008)

Glutathione Transferase (GST)-Activated Prodrugs
por: Ruzza, Paolo, et al.
Publicado: (2013)

An Orally Bioavailable (Mice) Prodrug of Glutathione
por: Crankshaw, Daune L., et al.
Publicado: (2021)

Peripheral macrophages not ADept at amyloid clearance
por: Jay, Taylor, et al.
Publicado: (2015)

So you want to be an ADEPT Fellow?
por: Donaghy, Grainne, et al.
Publicado: (2016)

Preclinical evaluation of the cardiac toxicity of HMR-1826, a novel prodrug of doxorubicin
por: Platel, D, et al.
Publicado: (1999)

Glutathione S-conjugates as prodrugs to target drug-resistant tumors
por: Ramsay, Emma E., et al.
Publicado: (2014)

Viral load is associated with abnormal serum levels of micronutrients and glutathione and glutathione-dependent enzymes in genotype 3 HCV patients
por: Razzaq, Zarish, et al.
Publicado: (2014)

2767. Impact of iron limitation on in vitro and in vivo activity of ceftazidime against A. baumannii
por: Eales, Brianna, et al.
Publicado: (2023)

The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model
por: Sandström, M, et al.
Publicado: (2004)

Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced α(1)-acid glycoprotein binding
por: Curtin, N J, et al.
Publicado: (1999)

Prodrug Approach for Increasing Cellular Glutathione Levels
por: Cacciatore, Ivana, et al.
Publicado: (2010)

Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours
por: Checkley, D, et al.
Publicado: (2003)

Challenges and opportunities integrating LLAMA into AdePT
por: Gruber, Bernhard Manfred, et al.
Publicado: (2023)

ADEPT - Abnormal Doppler Enteral Prescription Trial
por: Leaf, Alison, et al.
Publicado: (2009)

OneAPI for simulation: the AdePT project
por: Dosaru, Daniel-Florin
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_vdkcp53rr0legqtt5rmt2lueq0